Alnylam

Press Releases

Nov 06,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming Investor Conferences
PDF Version
Oct 30,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
PDF Version
Oct 29,2018
Summary ToggleHochschulmedizin Zurich and Alnylam Host Innovative Medicine Lecture on the Discovery and Clinical Applications of RNA interference (RNAi)
PDF Version
Oct 25,2018
Summary ToggleAlnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran
PDF Version
Oct 24,2018
Summary ToggleAlnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community
PDF Version
Oct 15,2018
Summary ToggleAlnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
PDF Version
Oct 10,2018
Summary ToggleAlnylam Appoints Dr. Margaret Hamburg to Board of Directors
PDF Version
Oct 04,2018
Summary ToggleAlnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1
PDF Version
Oct 03,2018
Summary ToggleAlnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
PDF Version
Oct 02,2018
Summary ToggleAlnylam Launches ONPATTRO™ (patisiran), the First-Ever RNAi Therapeutic, in Germany
PDF Version
Oct 02,2018
Summary ToggleAlnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting
PDF Version
Sep 28,2018
Summary ToggleAlnylam Announces Submission of New Drug Application in Japan for ONPATTRO™ (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
PDF Version
Sep 27,2018
Summary ToggleAlnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria
PDF Version
Sep 26,2018
Summary ToggleAlnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference
PDF Version
Sep 24,2018
Summary ToggleAlnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy
PDF Version
Sep 14,2018
Summary ToggleAlnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
PDF Version
Aug 30,2018
Summary ToggleAlnylam Receives Approval of ONPATTRO™ (patisiran) in Europe
PDF Version
Aug 29,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming September Investor Conferences
PDF Version
Aug 21,2018
Summary ToggleAlnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
PDF Version
Aug 10,2018
Summary ToggleAlnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO™ (patisiran)
PDF Version
Displaying 21 - 40 of 1005 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More